SOURCE: Gene Express, Inc.

March 04, 2008 09:15 ET

Gene Express' David Lester, Ph.D. to Participate in Keynote Panel Discussion at the Pharmaceutical Marketing Research Group's 2008 Annual National Conference

TOLEDO, OH--(Marketwire - March 4, 2008) - Gene Express, Inc. today announced that David S. Lester, Ph.D., Senior Vice President of Strategy and Corporate Development, will be one of three panel members discussing the dramatic changes the pharmaceutical industry is undergoing, at the Pharmaceutical Marketing Research Group's 2008 Annual National Conference in Phoenix, AZ, March 9-11.

Dr. Lester will be participating in the panel discussion entitled "Crystal Ball Gazing: The Pharmaceutical Industry in Transition -- Pharma 2020," immediately following the keynote speaker: Ken Fisher, CEO of Fisher Investments, Forbes magazine columnist and author of "The Only Three Questions That Count: Investing by Knowing What Other's Don't," on Monday, March 10. Dr. Lester's talk will focus on the impact of personalized medicine on the pharmaceutical industry, and how this relationship is changing.

To learn more about this event, please go to http://www.pmrg.org/

David S. Lester received his Ph.D. in Biological Sciences from Northwestern University and has held positions at Harvard University Medical School, the Weizmann Institute of Science (Israel) and National Institute of Neurological Disorders and Stroke at the National Institute of Health. He is currently serving as Senior Vice President at Gene Express, Inc. in charge of Strategy and Corporate Development. Dr. Lester is also President of Innovative Technologies for Health and Wellness (ITHW, Inc.). He has held executive positions, and played pivotal roles at Pfizer, in the Global Clinical Technology and Human Health Technologies Groups, as well as at Pharmacia Corp., and at the Center for Drug Evaluation and Research (CDER) at the Food and Drug Administration (FDA). Dr. Lester's Research interests have included the incorporation of innovative technologies into clinical trials for the use of biomarkers or surrogate endpoints. He has an extensive publication record including five edited volumes. Dr. Lester is active in numerous professional societies and has a strong record in public science policy activities.

About Pharmaceutical Marketing Research Group (PMRG)

The Pharmaceutical Marketing Research Group was founded in 1961. However, there were originally two PMRGs -- the Eastern Pharmaceutical Market Research Group (EPMRG) and the Western (WPMRG). All regions east of Chicago were included in the EPMRG and those west of Chicago were part of the WPMRG. The first recorded meeting of the EPMRG took place in the early 1950s at the Waldorf Astoria in New York City. Representatives from about six companies discussed pertinent issues of the day: new product tracking, how to fine-tune forecasting, how to measure promotional impact to determine return on investment, how the new trend of physicians moving into group practices affected prescribing. Today, PMRG is an independent, voluntary, non-profit association whose purpose is to stimulate improvement of marketing research and its utilization.

About Gene Express, Inc.

Gene Express, Inc. accelerates and enables drug and molecular diagnostic development by providing standardized genomic data. The Company's proprietary and patented StaRT-PCR™ (Standardized Reverse Transcription Polymerase Chain Reaction) platform technology for measuring gene expression levels in cells, clinical biopsies and blood is being used by numerous pharmaceutical concerns, as well as leading academic centers. The Company's $3 billion focus market for licensing and contract services includes the drug development, academic and molecular diagnostics segments. Additional information is available on the Company's website at www.geneexpressinc.com.

Any forecasts, plans, projections and other information contained in this press release describing events or results that may occur in the future are "forward-looking statements" as defined in the United States Private Securities litigation Reform Act of 1995. Forward-looking statements are subject to risks, uncertainties and important factors that are beyond the control of the Company that could cause actual results and events to differ materially from the results presently anticipated or projected. Readers are cautioned not to place undue reliance on these forward-looking statements and any such forward-looking statements are qualified in their entirety by reference to this cautionary statement. All forward-looking statements contained herein speak only as of the date of this release and are based on current expectations. The Company disclaims any obligation to update or revise any forward-looking statements.

Contact Information